Hadassah

New Lymphoma Drug, Thanks to Hadassah and Pennsylvania Physician/Scientists

Tuesday, Dec 29 2015

Nephrologist Prof. Michal Dranitzki Elhalel and Pennsylvania Pathologist Prof. Mark L. Tykocinski.

KAHR-102, a new immunotherapy drug to treat lymphoma, based on technology developed by Hadassah Medical Center Nephrologist Prof. Michal Dranitzki Elhalel and Pennsylvania Pathologist Prof. Mark L. Tykocinski, will begin clinical trials in mid-2016 at Hadassah, Tel-Hashomer, and Ichilov (Tel Aviv) medical centers.

Prof. Dranitzki Elhalel, now head of Nephrology at Hadassah, explored possible applications for the fusion protein CTLA4-Fast while a research fellow in 2000 at the University of Pennsylvania laboratory of Prof. Mark L. Tykocinski, who invented CTLA4, now known as KAHR-102. Prof. Tykocinski, then head of the Department of Pathology and Laboratory Medicine at the University of Pennsylvania, is now Dean of the Jefferson Medical School, Philadelphia, PA and Provost and Executive Vice President for Academic Affairs of the Thomas Jefferson University.

When she returned to Hadassah, Prof. Dranitzki Elhalel, with Prof. Tykocinski's encouragement,  continued to study this potential drug in her own laboratory, as well as other fusion proteins of the same class. KAHR-102, she explains,”is a fusion of portions of two naturally occurring human proteins into one chimeric protein with two functional ends. These two functional ends can bring synergistic effects, leading to highly targeted death of specific cells that can bind both sides of the protein, like malignant lymphoma cells.” She adds: “Interestingly, we found out that the resulting fusion protein has a unique structure that strongly increases its potency while conserving its specificity to the malignant lymphoma cells.”

KAHR medical Ltd., based on Prof. Tykocinski's patents, was established in 2007 by Hadasit, Hadassah’s technology transfer company. Prof. Tykocinski is Chair of the Scientific Clinical Advisory Board and Prof. Dranitzki Elhalel serves as KAHR’a Chief Scientist. Prof. Arnold Freedman, head of the Lymphoma Program at Dana Farber Cancer Institute, Boston, has recently joined KAHR’s Scientific Advisory Board.

The KAHR-102 study protocol was recently approved by the Israeli regulatory authorities, clearing the way for the clinical trial to begin mid-2016. The drug company, specializing in cancer and autoimmune disease drugs, reports that its products “form a new generation of biological drugs with great diversity and superior efficacy for the treatment of multiple cancer and autoimmune diseases.”

Comments

From: janine on February 14, 2016
can you have me? I have lymphoma,
From: janine on February 14, 2016
As a person living with lymphoma, I an excited to learn more. Can you help me?
From: Muriel on February 5, 2016
As a person living with lymphoma, I am very anxious to learn the results of the clinical trial. It sounds promising and I really hope it is effective.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Friday, Dec 15 2017

The Pediatric Intensive Care Unit (PICU) at Hadassah Hospital

An intimate video tour of the Pediatric Intensive Care Unit (PICU) at Hadassah Hospital highlights the miraculous recoveries of children given a second chance, with firsthand accounts from their grateful parents and their extraordinary doctors and nurses.

READ MORE ›
alt_text

Tuesday, Dec 12 2017

Hadassah Mount Scopus Rehab Gets Boost at Hadassah International Israel Gala Dinner

More than a thousand Israelis expressed their support for the eagerly anticipated new Hadassah Hospital Mount Scopus rehabilitation center for wounded soldiers and terror survivors at a gala event sponsored by Hadassah International Israel at the David International Hotel in Tel Aviv.

READ MORE ›
alt_text

Tuesday, Dec 12 2017

Older People Who Get Out Live Longer

A study led by Hadassah Physician Dr. Jeremy Michael Jacobs, Chair of the Hadassah Medical Organization’s Geriatric and Rehabilitation Complex, reveals that individuals between the ages of 70 and 90 who leave the house daily have a lower risk of mortality, independent of social, functional or medical status.

READ MORE ›
alt_text

Monday, Dec 11 2017

Twin boy Saved by Hadassah Experts and Cutting-Edge Technology

Simcha and his twin sister, Sarah, were born to a Jerusalem couple in their early forties, after years of hoping for children.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More